Search results for "Respiratory Medicine"

showing 10 items of 1534 documents

Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell l…

2019

Abstract Objectives To evaluate the effect on quality of life (QOL) of the addition of cisplatin to single-agent chemotherapy in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC) enrolled in two parallel phase 3 trials, MILES-3 and MILES-4. Patients and methods Advanced NSCLC pts, >70 years old, performance status (PS) 0–1, were eligible. Patients were randomly assigned to chemotherapy without or with cisplatin. EORTC QLQ C30 and LC13 questionnaires were planned at baseline, end of cycle 1 and end of cycle 2 in both trials and were used for joint QOL analysis. Trial-specific data including questionnaires at non-shared time-points were used for additional ana…

0301 basic medicinePulmonary and Respiratory MedicineQuality of lifeMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsNauseamedicine.medical_treatmentRandomizedNSCLCPhase 303 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineSurveys and QuestionnairesCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSurveys and QuestionnaireLung cancerAgedNeoplasm StagingCisplatinAged 80 and overChemotherapyAntineoplastic Combined Chemotherapy ProtocolPerformance statusbusiness.industryAlopeciamedicine.diseaseDysphagiaLung Neoplasm030104 developmental biologyTreatment OutcomeOncology030220 oncology & carcinogenesisVomitingStomatitis AphthousFemalemedicine.symptomCisplatinbusinessElderly patientStomatitis Aphthoumedicine.drugHuman
researchProduct

Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience.

2019

Hepatopulmonary syndrome (HPS) is a pulmonary vascular complication of liver disease that affects up to 30% of patients with cirrhosis [1]. Intrapulmonary vascular dilatations and shunts result in gas exchange abnormalities, ranging from elevated alveolar-arterial oxygen gradients with no hypoxemia to very severe hypoxemia [1, 2]. Currently, liver transplantation (LT) is the only treatment option [3]. The Model for End-Stage Liver Disease (MELD) is a scoring system for assessing liver disease severity that has been validated to predict the 3-months waitlist mortality, and is used by Eurotransplant for prioritising allocation of liver transplants [4]. Footnotes This manuscript has recently b…

0301 basic medicinePulmonary and Respiratory MedicineRiskScoring systemmedicine.medical_treatmentMedizinVascular complicationLiver transplantationEnd Stage Liver Disease03 medical and health sciences0302 clinical medicineSevere hypoxemiaNothingMedicineHumansRegistriesProportional Hazards ModelsRetrospective Studiesbusiness.industryConflict of interestTreatment optionsLiver TransplantationEuropeOxygen030104 developmental biologyTreatment OutcomeLaw030211 gastroenterology & hepatologybusinessProduction teamHepatopulmonary SyndromeThe European respiratory journal
researchProduct

Staphylococcus aureusand its IgE-inducing enterotoxins in asthma: current knowledge

2020

While immunoglobulin (Ig) E is a prominent biomarker for early-onset, its levels are often elevated in non-allergic late-onset asthma. However, the pattern of IgE expression in the latter is mostly polyclonal, with specific IgEs low or below detection level albeit with an increased total IgE. In late-onset severe asthma patients, specific IgE to Staphylococcal enterotoxins (se-IgE) can frequently be detected in serum, and has been associated with asthma, with severe asthma defined by hospitalisations, oral steroid use and decrease in lung function. Recently,se-IgE was demonstrated to even predict the development into severe asthma with exacerbations over the next decade.Staphylococcus aureu…

0301 basic medicinePulmonary and Respiratory Medicinebiologybusiness.industrymedicine.medical_treatmentInnate lymphoid cellDegranulationEosinophilImmunoglobulin E03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureCytokine030228 respiratory systemMucosal immunologyImmunologySuperantigenbiology.proteinMedicineAntibodybusinessEuropean Respiratory Journal
researchProduct

P1.13-16 The Diagnostic Accuracy of Circulating Tumor DNA for the Detection of EGFR-T790M Mutation in NSCLC: A Systematic Review and Meta-Analysis

2018

0301 basic medicinePulmonary and Respiratory Medicinebusiness.industryDiagnostic accuracyEGFR T790M03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyCirculating tumor DNA030220 oncology & carcinogenesisMeta-analysisMutation (genetic algorithm)Cancer researchMedicinebusinessJournal of Thoracic Oncology
researchProduct

71P Exosomes isolated in plasma of non-small cell lung cancer patients contain microRNA related to the EGFR pathway: Proof of concept

2016

0301 basic medicinePulmonary and Respiratory Medicinebusiness.industrymedicine.diseaseMicrovesiclesCell biology03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesismicroRNAmedicineEgfr signalingNon small cellLung cancerbusinessJournal of Thoracic Oncology
researchProduct

The Novel Oral Anticoagulants for Acute Venous Thromboembolism: Is Warfarin Dead?

2017

The direct oral anticoagulants (DOACs) have been compared with parenteral anticoagulants and vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE) in several robust studies. DOACs have shown similar efficacy in preventing recurrent VTE and significant reductions in critical site (intracranial) bleeding, fatal bleeding, major and nonmajor bleeding. Warfarin and other VKAs are not dead as treatment modalities for VTE. A better way to describe the current situation is to use a boxing expression, “down but not out.” VKAs and parenteral anticoagulants still have a role to play in the management of VTE in several clinical settings. In indications where DOACs can be used, …

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyAdministration OralClinical settingsVitamin kCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicineSecondary PreventionmedicineHumanscardiovascular diseasesIntensive care medicineOral anticoagulationCerebral Hemorrhagebusiness.industryWarfarinAnticoagulantsVenous ThromboembolismSafety profile030104 developmental biologyTreatment modalityvenous thromboembolism oral anticoagulation warfarin non-VKA oral anticoagulants safety efficacy030220 oncology & carcinogenesisWarfarinbusinessVenous thromboembolismmedicine.drug
researchProduct

JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study

2018

BackgroundPulmonary hypertension (PH) is a common disorder in patients with idiopathic pulmonary fibrosis (IPF) and portends a poor prognosis. Recent studies using vasodilators approved for PH have failed in improving IPF mainly due to ventilation (V)/perfusion (Q) mismatching and oxygen desaturation. Janus kinase type 2 (JAK2) is a non-receptor tyrosine kinase activated by a broad spectrum of profibrotic and vasoactive mediators, but its role in PH associated to PH is unknown.ObjectiveThe study of JAK2 as potential target to treat PH in IPF.Methods and resultsJAK2 expression was increased in pulmonary arteries (PAs) from IPF (n=10; 1.93-fold; P=0.0011) and IPF+PH (n=9; 2.65-fold; P<0.00…

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyHypertension PulmonaryBlotting WesternMyocytes Smooth MuscleFluorescent Antibody TechniqueVasodilationVascular RemodelingReal-Time Polymerase Chain ReactionVascular remodelling in the embryo03 medical and health sciencesIdiopathic pulmonary fibrosisTransforming Growth Factor betaRight ventricular hypertrophyInternal medicinepulmonary hypertensionAnimalsHumansMedicineRNA Small InterferingRats WistarCells CulturedCell ProliferationBKCaJanus kinase 2biologybusiness.industryEndothelial CellsJanus Kinase 2idiopathic pulmonary fibrosismedicine.diseaseImmunohistochemistryPulmonary hypertensionIdiopathic Pulmonary FibrosisTriterpenesRatsPhenotype030104 developmental biologyJAK2biology.proteinCardiologyAnimal studiesJanus kinasebusinessSignal TransductionPulmonary artery smooth muscle cells Pulmonary artery endothelial cells.Thorax
researchProduct

Morphomolecular motifs of pulmonary neoangiogenesis in interstitial lung diseases

2019

The pathogenetic role of angiogenesis in interstitial lung diseases (ILDs) is controversial. This study represents the first investigation of the spatial complexity and molecular motifs of microvascular architecture in important subsets of human ILD. The aim of our study was to identify specific variants of neoangiogenesis in three common pulmonary injury patterns in human ILD.We performed comprehensive and compartment-specific analysis of 24 human lung explants with usual intersitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP) and alveolar fibroelastosis (AFE) using histopathology, microvascular corrosion casting, micro-comupted tomography based volumetry and gene expression…

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyPathologyAngiogenesisVascular remodelling in the embryoNeovascularization03 medical and health sciences0302 clinical medicineVascularitymedicineHumansIdiopathic Interstitial PneumoniasLungIdiopathic interstitial pneumoniaLungNeovascularization Pathologicbusiness.industryrespiratory systemmedicine.diseaserespiratory tract diseases3. Good healthPneumonia030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisHistopathologymedicine.symptomLung Diseases InterstitialTomography X-Ray ComputedbusinessEuropean Respiratory Journal
researchProduct

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classificatio…

2016

AbstractThe IASLC Staging and Prognostic Factors Committee has collected a new database of 94,708 cases donated from 35 sources in 16 countries around the globe. This has now been analysed by our statistical partners at Cancer Research And Biostatistics and, in close collaboration with the members of the committee proposals have been developed for the T, N, and M categories of the 8th edition of the TNM Classification for lung cancer due to be published late 2016. In this publication we describe the methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition.

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyPathologyLung NeoplasmsStagingMedizinPrognostic factors1102 Cardiovascular Medicine And HaematologyLung cancer; Prognostic factors; Staging03 medical and health sciences0302 clinical medicineSeer programmedicineHumansOncology & CarcinogenesisStage (cooking)Lung cancerNeoplasm Stagingbusiness.industryGeneral surgeryInternational Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions1103 Clinical SciencesPrognosismedicine.diseaseInternational Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions030104 developmental biologyOncology030220 oncology & carcinogenesisNeoplasm stagingBiostatisticsLung cancer stagingLung cancerbusinessSEER Program
researchProduct

The Culpability of Respiratory Viruses in Pneumonia-Related Acute Respiratory Failure

2018

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industrymedia_common.quotation_subject030106 microbiologyMEDLINECritical Care and Intensive Care Medicinemedicine.disease03 medical and health sciencesPneumonia0302 clinical medicineJurymedicineAcute respiratory failure030212 general & internal medicineRespiratory systemCardiology and Cardiovascular MedicineIntensive care medicinebusinessmedia_commonCulpabilityChest
researchProduct